康希诺生物(06185)发布前三季度业绩 归母净利润1444.01万元

Core Viewpoint - 康希诺生物 reported a significant improvement in financial performance for the first three quarters of 2025, with a notable increase in revenue and a shift from loss to profit [1] Financial Performance - The company achieved an operating revenue of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to shareholders was 14.44 million yuan, a turnaround from a net loss of 222 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.06 yuan [1]